Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Welti, S. Loges, S. Dimmeler, P. Carmeliet (2013)
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.The Journal of clinical investigation, 123 8
B. Rini (2010)
Biomarkers: hypertension following anti-angiogenesis therapy.Clinical advances in hematology & oncology : H&O, 8 6
(2015)
Renal cell carcinoma programmeddeath-ligand1,anewdirecttargetofhypoxiainduciblefactor-2Alpha, is regulatedbyvonHippel-Lindau genemutation status
(2013)
Recentmolecular discoveriesinangiogenesisandantiangiogenictherapiesin cancer
S. Macher-Goeppinger, M. Keith, V. Endris, R. Penzel, K. Tagscherer, S. Pahernik, M. Hohenfellner, H. Gardner, C. Grüllich, P. Schirmacher, W. Roth (2016)
MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive markerOncotarget, 8
(2005)
Comparisonofpredic - tive accuracy of four prognosticmodels for nonmetastatic renal cell carcinoma after nephrectomy : A multi - center Europeanstudy
(2010)
hypertension followingantiangiogenesis therapy
A. Semaan, D. Dietrich, Dominik Bergheim, Jörn Dietrich, J. Kalff, V. Branchi, H. Matthaei, G. Kristiansen, H. Fischer, D. Goltz (2017)
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxiaVirchows Archiv, 470
Su-Jin Shin, Y. Jeon, Pil-Jong Kim, Y. Cho, J. Koh, D. Chung, H. Go (2016)
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins StatusAnnals of Surgical Oncology, 23
M. Ruf, H. Moch, P. Schraml (2016)
PD‐L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinomaInternational Journal of Cancer, 139
(2016)
grammed cell deathligand 1 expression is associated with a favourable immunemicroenvironmentandbetteroverall survival instageIpulmonarysquamouscellcarcinoma
R. Siegel, K. Miller, A. Jemal (2017)
Cancer statistics, 2017CA: A Cancer Journal for Clinicians, 67
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
(2016)
PD - L 1 expression is regulatedby hypoxia inducible factor in clear cell renal cell carcinoma
B. Rini (2010)
New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and ResistanceClinical Cancer Research, 16
M. Matsuki, Y. Adachi, Y. Ozawa, Takayuki Kimura, Taisuke Hoshi, K. Okamoto, O. Tohyama, K. Mitsuhashi, Atsumi Yamaguchi, J. Matsui, Y. Funahashi (2017)
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimusCancer Science, 108
(2014)
Aphase 1 bclinicaltrial of the multitargeted tyrosine kinase inhibitor lenvatinib ( E 7080 ) in combination with everolimus for treatment of metastatic renal cell carcinoma ( RCC )
K. Gupta, Jeffrey Miller, Jim Li, M. Russell, C. Charbonneau (2008)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.Cancer treatment reviews, 34 3
(2016)
Qualityof lifeinpatients withadvancedrenalcellcarcinomagivennivolumabversus everolimusin CheckMate 025 : A randomised , open - label , phase 3 trial
Y. Shaked, E. Henke, J. Roodhart, P. Mancuso, M. Langenberg, M. Colleoni, L. Daenen, S. Man, P. Xu, U. Emmenegger, T. Tang, Zhen-ping Zhu, L. Witte, R. Strieter, F. Bertolini, E. Voest, R. Benezra, R. Kerbel (2008)
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.Cancer cell, 14 3
N. Tannir, G. Schwab, V. Grünwald (2017)
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell CarcinomaCurrent Oncology Reports, 19
R. Motzer, Thomas Hutson, H. Glen, M. Michaelson, A. Molina, T. Eisen, J. Jassem, J. Zolnierek, J. Maroto, B. Mellado, B. Melichar, J. Tomasek, A. Kremer, H. Kim, K. Wood, C. Dutcus, J. Larkin (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.The Lancet. Oncology, 16 15
(2017)
Cabozantinib : anactive novel multikinase inhibitor in renal cell carcinoma
B. Escudier, T. Eisen, C. Porta, J. Patard, V. Khoo, F. Algaba, P. Mulders, V. Kataja (2012)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 7
(2000)
Up-regulationofhypoxia-induciblefactorsHIF-1alphaand HIF-2alphaundernormoxicconditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.Oncogene
Y. Messai, S. Gad, M. Noman, G. Teuff, S. Couvé, B. Janji, Solenne Kammerer, N. Rioux-leclerc, M. Hasmim, S. Ferlicot, V. Baud, A. Méjean, D. Mole, S. Richard, A. Eggermont, L. Albiges, F. Mami-Chouaib, B. Escudier, S. Chouaib (2016)
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.European urology, 70 4
B. Escudier, P. Sharma, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, H. Gurney, F. Donskov, K. Peltola, J. Wagstaff, T. Gauler, T. Ueda, Huanyu Zhao, I. Waxman, R. Motzer (2017)
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.European urology, 72 6
C. Bazelaire, D. Alsop, D. George, I. Pedrosa, Yongyu Wang, M. Michaelson, N. Rofsky (2008)
Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell CarcinomaClinical Cancer Research, 14
A. Pircher, K. Jöhrer, F. Kocher, N. Steiner, I. Graziadei, I. Heidegger, R. Pichler, N. Leonhartsberger, C. Kremser, J. Kern, G. Untergasser, E. Gunsilius, W. Hilbe (2016)
Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapiesOncotarget, 7
R. Motzer, B. Rini, D. McDermott, B. Redman, T. Kuzel, M. Harrison, U. Vaishampayan, H. Drabkin, S. George, T. Logan, K. Margolin, E. Plimack, A. Lambert, I. Waxman, H. Hammers (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 13
(2016)
Renal cell carcinoma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up
M. Krieg, R. Haas, H. Brauch, T. Acker, I. Flamme, K. Plate (2000)
Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of functionOncogene, 19
BI Rini (2010)
New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistanceCancer Res, 16
R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Yoshihiko Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, P. Sharma (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.The New England journal of medicine, 373 19
D. Cella, V. Grünwald, P. Nathan, J. Doan, H. Dastani, F. Taylor, B. Bennett, M. Derosa, S. Berry, K. Broglio, E. Berghorn, R. Motzer (2016)
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.The Lancet. Oncology, 17 7
Karly Garnock-jones, G. Keating (2009)
Everolimus: in advanced renal cell carcinoma.Drugs, 69 15
G. Bergers, D. Hanahan (2008)
Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 8
(2015)
Nivolumabver - sus Everolimus in advanced renalcell carcinoma
L. Cindolo, J. Patard, P. Chiodini, L. Schips, V. Ficarra, J. Tostain, A. taille, V. Altieri, B. Lobel, R. Zigeuner, W. Artibani, F. Guillé, C. Abbou, L. Salzano, C. Gallo (2005)
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomyCancer, 104
Lijun Zhou, Xian-de Liu, Mianen Sun, Xuesong Zhang, P. Germán, S. Bai, Z. Ding, N. Tannir, C. Wood, S. Matin, J. Karam, P. Tamboli, K. Sircar, P. Rao, E. Rankin, D. Laird, A. Hoang, C. Walker, A. Giaccia, E. Jonasch (2016)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene, 35
M. Noman, S. Chouaib (2014)
Targeting hypoxia at the forefront of anticancer immune responsesOncoImmunology, 3
(2016)
Cabozantinibversus everolimus in advanced renal cell carcinoma ( METEOR ) : final results from a randomised , open - label , phase 3 trial
(2000)
Up - regulationofhypoxiainduciblefactorsHIF1 alphaand HIF2 alphaundernormoxicconditions in renal carcinoma cells by von HippelLindau tumor suppressor gene loss of function
Ching-Yao Yang, Mong-Wei Lin, Yih-Leong Chang, Chen‐Tu Wu, Pan‐Chyr Yang (2016)
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.European journal of cancer, 57
T. Choueiri, B. Escudier, T. Powles, N. Tannir, P. Mainwaring, B. Rini, H. Hammers, F. Donskov, B. Roth, K. Peltola, J. Lee, D. Heng, M. Schmidinger, N. Agarwal, C. Sternberg, D. McDermott, D. Aftab, C. Hessel, C. Scheffold, G. Schwab, Thomas Hutson, S. Pal, R. Motzer (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.The Lancet. Oncology, 17 7
M. Noman, G. Desantis, B. Janji, M. Hasmim, S. Karray, P. Dessen, V. Bronte, S. Chouaib (2014)
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activationThe Journal of Experimental Medicine, 211
A. Molina, Thomas Hutson, J. Larkin, A. Gold, K. Wood, D. Carter, R. Motzer, M. Michaelson (2013)
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Cancer Chemotherapy and Pharmacology, 73
G. Gibney, S. Aziz, R. Camp, P. Conrad, Brian Schwartz, C. Chen, W. Kelly, Harriet Kluger (2013)
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 24 2
P. Nikolinakos, N. Altorki, D. Yankelevitz, H. Tran, Shaoyu Yan, D. Rajagopalan, W. Bordogna, L. Ottesen, J. Heymach (2010)
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.Cancer research, 70 6
Yuji Yamamoto, J. Matsui, T. Matsushima, H. Obaishi, K. Miyazaki, Katsuji Nakamura, O. Tohyama, T. Semba, Atsumi Yamaguchi, S. Hoshi, Fusayo Mimura, T. Haneda, Y. Fukuda, Jun-ichi Kamata, Keiko Takahashi, M. Matsukura, T. Wakabayashi, M. Asada, K. Nomoto, Tatsuo Watanabe, Z. Dezső, K. Yoshimatsu, Y. Funahashi, A. Tsuruoka (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageVascular Cell, 6
(2015)
Programmed cell death-ligand 1 expression is associated with a favourable immunemicroenvironmentandbetteroverall survival instageIpulmonarysquamouscellcarcinoma
The era of antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway has become a mainstay in the treatment of metastatic renal cell carcinoma (mRCC), showing primary responses in 65–70% of patients. Nevertheless, most of those patients progress to angiogenesis inhibitors over time due to different modes of resistance (adaptive and intrinsic). Both in vitro and in vivo analyses provided evidence that PD-L1 upregulation in hypoxia conditions is dependent on hypoxia-inducible factor (HIF)-2alpha and is associated with an overexpression of VEGF. Thus, additional blockade of PD-L1 along with inhibition of angiogenesis pathways seems to represent a novel and innovative treatment concept in mRCC. In this short review, we provide an overview on ongoing phase III trials combining antiangiogenic therapies with checkpoint inhibitors in the first-line setting. Moreover, we critically analyze the impact of recently approved therapeutic antiangiogenic agents and checkpoint inhibitors after progression to first-generation tyrosine kinase inhibitors and their mode of action. In addition, response and resistance hypotheses and biomarkers to antiangiogenic therapy in clinical practice are critically discussed.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Aug 11, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.